UK Markets close in 3 hrs 25 mins
  • FTSE 100

    6,332.24
    -30.69 (-0.48%)
     
  • FTSE 250

    19,227.90
    -168.44 (-0.87%)
     
  • AIM

    1,038.98
    +0.95 (+0.09%)
     
  • GBP/EUR

    1.1176
    -0.0035 (-0.31%)
     
  • GBP/USD

    1.3331
    -0.0025 (-0.1893%)
     
  • BTC-GBP

    12,816.66
    -38.39 (-0.30%)
     
  • CMC Crypto 200

    333.98
    -36.54 (-9.86%)
     
  • S&P 500

    3,629.65
    -5.76 (-0.16%)
     
  • DOW

    29,872.47
    -173.77 (-0.58%)
     
  • CRUDE OIL

    45.28
    -0.43 (-0.94%)
     
  • GOLD FUTURES

    1,810.20
    -1.00 (-0.06%)
     
  • NIKKEI 225

    26,644.71
    +107.40 (+0.40%)
     
  • HANG SENG

    26,894.68
    +75.23 (+0.28%)
     
  • DAX

    13,317.38
    +30.81 (+0.23%)
     
  • CAC 40

    5,596.10
    +29.31 (+0.53%)
     

What Type Of Shareholders Make Up Altimmune, Inc.'s (NASDAQ:ALT) Share Registry?

Simply Wall St
·5-min read

If you want to know who really controls Altimmune, Inc. (NASDAQ:ALT), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Companies that have been privatized tend to have low insider ownership.

Altimmune is a smaller company with a market capitalization of US$231m, so it may still be flying under the radar of many institutional investors. In the chart below, we can see that institutions are noticeable on the share registry. Let's delve deeper into each type of owner, to discover more about Altimmune.

Check out our latest analysis for Altimmune

NasdaqGM:ALT Ownership Breakdown July 8th 2020
NasdaqGM:ALT Ownership Breakdown July 8th 2020

What Does The Institutional Ownership Tell Us About Altimmune?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

We can see that Altimmune does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone, since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Altimmune's historic earnings and revenue, below, but keep in mind there's always more to the story.

NasdaqGM:ALT Earnings and Revenue Growth July 8th 2020
NasdaqGM:ALT Earnings and Revenue Growth July 8th 2020

We note that hedge funds don't have a meaningful investment in Altimmune. Our data shows that VR Adviser, LLC is the largest shareholder with 22% of shares outstanding. With 8.2% and 3.0% of the shares outstanding respectively, Velocity Pharmaceutical Development, LLC and Renaissance Technologies Corp. are the second and third largest shareholders. In addition, we found that Vipin Garg, the CEO has 1.5% of the shares allocated to his name

On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.

Insider Ownership Of Altimmune

The definition of company insiders can be subjective, and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board; and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board, themselves.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our most recent data indicates that insiders own some shares in Altimmune, Inc.. As individuals, the insiders collectively own US$4.3m worth of the US$231m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.

General Public Ownership

The general public, mostly retail investors, hold a substantial 56% stake in ALT, suggesting it is a fairly popular stock. This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and the dividend payout ratio.

Private Equity Ownership

With an ownership of 22%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Private Company Ownership

It seems that Private Companies own 8.2%, of the ALT stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Be aware that Altimmune is showing 3 warning signs in our investment analysis , and 2 of those are a bit unpleasant...

Of course this may not be the best stock to buy. Therefore, you may wish to see our free collection of interesting prospects boasting favorable financials.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.